News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
February, 2025
February 2025
M T W T F S S
 12
3456789
10111213141516
17181920212223
2425262728  
Paolo Tarantino: You don’t always need a fancy new drug to impact patients QoL
Photo of Paolo Tarantino from X
Mar 4, 2024, 17:58

Paolo Tarantino: You don’t always need a fancy new drug to impact patients QoL

Paolo Tarantino, Medical Oncologist and Research Fellow at Dana-Farber Cancer Institute, shared a post on X/Twitter:

”You don’t always need a fancy new drug to impact patients QoL. In the D-TORCH phase 3 trial, the use of topical diclofenac during capecitabine reduced the risk of G2-3 HFS (3.8% vs 15%, p=0.03) and of HFS-related dose reductions. Should be considered SoC.”

Paolo Tarantino: You don’t always need a fancy new drug to impact patients QoL

Read further.
Source: Paolo Tarantino/X

cancer capecitabine ClinicalTrials D-TORCH Diclofenac Hand Foot Syndrome healthcare medicine OncoDaily Oncology Paolo Tarantino Phase 3 Trial quality of life Standard of Care
Special Coverage
Opinion
Feb 22, 2025, 13:10
Senator Edward Markley in Response to OncoDaily About Pediatric Cancer Funding
Science
Feb 22, 2025, 13:10
Why immunotherapy has struggled in EGFR+ lung cancer - EGFR Positive Lung Cancer UK
Blog
Feb 22, 2025, 13:04
Debate session on the management of stage III NSCLC in the IO era - ESTRO
Celebrities
Feb 22, 2025, 11:40
Remembering Saxophonist James Casey: His Battle with Colon Cancer and Advocacy
Career
Feb 22, 2025, 11:36
Joseph H. Antin Received ASTCT Lifetime Achievement Award at 2025 Tandem Meetings
Science
Feb 22, 2025, 11:28
Myeloma Paper of the Day, February 22nd, suggested by Robert Orlowski
Blog
Feb 22, 2025, 11:22
Yan Leyfman: Great experience speaking at the NSHSS Pre-Medicine Workshop
Insight
Feb 22, 2025, 11:15
Henrik Ullum: The urgent need to protect WHO is also an opportunity
Oncolibrary
Feb 22, 2025, 11:02
New Paper Alert: Efficacy of Zenocutuzumab in NRG1 Fusion–Positive Cancer
Blog
Feb 22, 2025, 10:57
Tsetsegsaikhan Batmunkh: Factsheets for parents on childhood cancers and essential medicines in the Mongolian
Blog
Feb 22, 2025, 10:47
Akhilesh Bind: Advancing political leadership for equitable cancer care
Blog
Feb 22, 2025, 10:41
Nominations close for the 2025 Szent-Györgyi Prize for Progress in Cancer Research - NFCR